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The acetylated isoforms of histone H4 from mouse lymphosarcoma cells treated with HDAC
inhibitors trichostatin A (TSA) and depsipeptide (DDP) were separated by acetic acid
urea-polyacrylamide gel electrophoresis (AU-PAGE), in-gel digested, and analyzed by matrix
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and
liquid chromatography tandem mass spectrometry (LC-MS/MS). The acetylation pattern of
histone H4 in mouse lymphosarcoma cells induced by TSA was established in which
acetylation initially occurred at K16 followed by K12 and then K8 and/or K5. An identical
order of acetylation was found for cells treated with DDP. (J Am Soc Mass Spectrom 2005, 16,
1641–1653) © 2005 American Society for Mass SpectrometryThe core histones form an octamer that consists ofa tetramer of H4-H3 and two dimers of H2A-H2Bwhich organize with double stranded DNA to
form nucleosomes [1, 2]. Histones are highly positively-
charged and highly conserved throughout eukaryotic
evolution. Their posttranslational modifications (acetyla-
tion, methylation, phosphorylation, ADP ribosylation,
and ubiquitination, etc.) are proposed to affect the inter-
actions between DNA and other chromatin associated
proteins, thus regulating the higher order structure of
chromatin and in turn gene transcription [3]. Histone
acetylation and deacetylation are controlled by histone
acetyltransferases (HATs) and histone deacetylases
(HDACs). HDAC inhibitors increase acetylation levels
and induce open chromatin structure and increased gene
transcription. HDAC inhibitors have been found to func-
tion as potential chemotherapeutic reagents as they arrest
cell growth, differentiation, and/or apoptosis in many
tumor cell types [4].
Although nucleosome formation is essential to com-
pact the genome within the nuclei, it also impedes
access of most transcription factors to their cognate sites
on DNA. Most of the extrinsic and intrinsic signal
transduction pathways manifest their biological re-
sponse by modulating gene expression that requires
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of nucleosomes is mediated through altering posttrans-
lational modifications of NH2-terminal tails of histones
as well as by ATP-dependent chromatin remodeling
machinery (for review, see references [5–7]. Depending
upon the modification states of core histones, the asso-
ciated genes can be activated or repressed as they
interact with coactivators or corepressors. In eukaryotic
cells, acetylation of core histones at the NH2-terminal
lysines and phosphorylation at serine-10 of H3 usually
are markers of active genes, whereas methylated his-
tones are associated with both active and repressed
promoters depending upon the site of methylation. For
example, K9 methylation (K9-Me) in H3 is exclusively
associated with transcriptionally repressed genes
whereas K4-Me in H3 is a marker of active promoters.
In contrast, methylation of R17 in H3 and R3 in H4 is a
signature of genes activated by steroid hormone recep-
tors [8, 9]. Lysines can be mono-, di- or trimethylated
whereas arginines can be mono- or di- (asymmetrical or
symmetrical) methylated [3, 6, 8 –10]. Gene activation
also depends on the degree of histone methylation [9].
Gene expression can be turned on or off very rapidly by
reversible acetylation/deacetylation or phosphoryla-
tion/dephosphorylation by cellular HATs/HDACs and
kinases/phosphatases. In contrast, methylation was
thought to be irreversible as no specific histone demeth-
ylase had been identified [11]. However, LSD1
(KIAA0601), a nuclear homolog of amine oxidases, has
recently been reported to function as a histone demeth-
ylase and transcriptional corepressor, which is specific
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1642 REN ET AL. J Am Soc Mass Spectrom 2005, 16, 1641–1653to demethylate lysine 4 of histone H3 [12]. Another
study has shown that methylated arginines of H3 and
H4 can be converted to citrulline by peptidylarginine
deiminase 4, releasing methylamine [13, 14]. These
findings suggest that methylation marks on histones
can be also dynamically regulated by histone methyl-
ases and demethylases or by cellular enzymatic machin-
ery.
Posttranslational modifications on core histones also
act in a combinatorial, sequential or antagonistic man-
ner to activate or repress gene expression. For example,
K9- and K14-acetylation (Ac), and S10-phosphorylation
(S10-P) are signature markers on early growth response
genes stimulated with growth factors [15]. Similarly,
K4-Me and K14-Ac on the same H3 and R3-Me and
K5-Ac on H4 are symbols of active genes indicating that
modifications at one site sequentially or synergistically
modulate those at other sites [6]. In contrast, some
modifications are mutually exclusive, e.g., S10-P pre-
vents methylation at K9 of H3 and S18-P of H4 excludes
methylation at K20 but facilitates K16 acetylation.
Therefore, analysis of different posttranslational modi-
fications occurring upon a single molecule is critical to
explore their potential role in gene regulation. To iden-
tify these modification patterns, we explored systematic
mass spectrometric analysis of histone H4 from mouse
lymphosarcoma cells treated with HDAC inhibitors.
Traditional methods, such as micro-sequencing and
immunoassay, are limited by the dependence on large
amounts of purified samples and the availability of site
specific antibodies [16, 17]. The successful development
of soft ionization techniques, such as electrospray ion-
ization (ESI) [18 –20] and matrix assisted laser desorp-
tion/ionization (MALDI) [21–23], have spurred the
adoption of mass spectrometry as a powerful technique
for protein characterization. Mass spectrometry has
been demonstrated to be a very powerful technique to
identify the posttranslational modifications of core his-
tones [24 –33]. Purification and separation of histone
isoforms also play a critical role in the accurate and fast
identification of histone posttranslational modifica-
tions. Core histones can be separated by reverse phase
high-pressure liquid chromatography but without res-
olution of the different isoforms [26, 27]. Hydrophilic-
interaction liquid chromatography (HILIC) uses a weak
cation exchange column and an increasing salt concen-
tration gradient to elute different acetylation, phosphor-
ylation and methylation isoforms [34, 35]. However, in
HILIC the high organic and salt concentrations are not
directly amenable to online MS analysis without exten-
sive workup.
Acetic acid urea-polyacrylamide gel electrophoresis
(AU-PAGE) separates proteins based on their size and
effective charge. Acetylation of the positively charged
-amino lysine side-chain residues causes a decrease of
the effective charge and the mobility of histones in gels.
It has been shown that different acetylation isoforms of
histone H4 and H3 can be separated by AU-PAGE and
only micrograms of the whole histone mixture arerequired for further MS analysis [36]. The enzymatic
in-gel digests can be used to identify the sites of
posttranslational modifications by mass spectrometry.
Person used MALDI-TOF MS and LC-MS/MS to iden-
tify histone H4 modifications from in-gel chymotrypsin
digestion with H4 separated on Triton AU gels [37]. We
modified their approach for the use of trypsin to
examine the acetylation profiles of histone H4 from
mouse lymphosarcoma cells treated with TSA and
depsipetide. Trypsin digests are much easier to obtain
reproducible digestion profiles than chymotrypsin.
Since lysine acetylation inhibits cleavage by trypsin, this
enzyme also provides additional diagnostic informa-
tion useful in sequencing the sites of modification. Here
we present this approach as a rapid, robust and highly
reproducible method to profile acetylation on the NH2-
terminal tails of histone H4 for cancer cells treated with
HDAC inhibitor chemotherapies.
Experimental
Materials
HDAC inhibitor trichostatin A (TSA) was purchased
from Sigma Chemical Company (St. Louis, MO) and
depsipeptide (DDP) was obtained from the Develop-
mental Therapeutics Program, Division of Cancer
Treatment, National Cancer Institute (Bethesda, MD).
Modified sequencing grade trypsin (V511) was pur-
chased from Promega (St. Louis, MO). The MALDI
matrix, -cyano-4-hydroxy-cinnamic acid (HCCA),
was purchased from Bruker Daltonics (Billerica, MA).
All other chemicals were analytical or HPLC grade.
Cell Culture and Treatment of Cells with HDAC
Inhibitors TSA, and DDP
Lymphosarcoma cells were grown in RPMI 1640 me-
dium (Invitrogen, Carlsbad, CA) containing 20 mM
Hepes, 2% sodium bicarbonate, 1 mM glutamine, 10 nM
2-mercaptoethanol, and 5% FBS at 37 °C in the presence
of 5% CO2 [38]. Cells were treated for 12 h with TSA
(300 nM) or DDP (10 nM) from a 1000X stock dissolved
in methanol before isolation of histones. Control cells
were treated with the same volume of methanol.
Histone Purification
Histones were isolated from lymphosarcoma cells as
described previously [39]. Briefly, cells (5  107) were
harvested by centrifugation at 4 °C at 2000  g for
5 min, washed with PBS, and resuspended in 5 ml of
nuclear isolation buffer consisting of 0.25 M sucrose,
10 mM Tris HCl (pH 7.5), 1.5 mM MgCl2, 0.5% Triton
X-100, 0.5 mM PMSF, protease inhibitor cocktail
(Sigma). Cells were either homogenized in a dounce
homogenizer on ice with tight pestle or vortexed until
90 to 95% of plasma membrane of the cells were broken.
Nuclei were isolated by spinning at 3000  g for 5 min
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Triton X-100. Histones were extracted from the nuclei
with 0.4 N ice-cold H2SO4 for 30 min and insoluble
particles were removed by centrifugation at 15,000  g
for 10 min. Histones were precipitated from the super-
natant with 10 volumes of acetone and collected by
centrifugation at 22,000  g for 30 min. The pellet was
washed twice with ice-cold acetone, dissolved in water,
and stored at 80 °C in small aliquots.
Acetic Acid-Urea Polyacrylamide Gel
Electrophoresis (AU-PAGE) Separation
of Acetylated Histone Isoforms
Acetic acid urea-polyacrylamide gel electrophoresis
(AU-PAGE) was performed as described earlier [39]
with some modifications. 50 g of histones from con-
trol, TSA, and DDP treated cells were separated by
AU-PAGE (15% acrylamide, acrylamide:bisacrylamide:
38.7:1.3) at 300 V (constant voltage) overnight (20 h) at
4 °C using 5% acetic acid as the running buffer. The gels
were fixed in 50% ethanol/10% acetic acid at room
temperature for 4 h, then washed twice (30 min each)
with 50% methanol/5% acetic acid, stained with
Coomassie Brilliant Blue for 30 min and then destained
in 30% methanol/10% acetic acid until the background
was clear.
Trypsin In-Gel Digestion
Each of the gel bands was excised into small pieces and
two bands of the same isoforms combined. The gel
pieces were washed twice (one h each) with freshly
made 50% methanol/5% acetic acid solution. Gel pieces
were dehydrated in 200 l ACN for 5 min followed by
a 5 min rehydration in 200 l 100 mM NH4HCO3 twice.
Gels were dehydrated in ACN again for 5 min and
dried in speed vacuum for 2 to 3 min. Thirty l of
freshly prepared trypsin (20 ng/l in 50 mM
NH4HCO3) were added to each sample and rehydrated
on ice for 10 min, then digested at 37 °C for 1 or 2 h.
Tryptic digested peptides were extracted with 50%
ACN/5% formic acid three times and were dried to
about 10 l in the speed vacuum.
Matrix Assisted Laser Desorption/Ionization
Time-of-Flight (MALDI-TOF) MS
MALDI-TOF MS was performed on a Bruker Reflex III
(Bruker, Breman, Germany). The mass spectrometer
was operated in linear, positive ion mode. The N2 laser
power was adjusted to the minimum intensity neces-
sary to obtain signal. The accelerating voltage was
maintained at 28 kV. The instrument was calibrated
with protein standards bracketing the molecular
weights of the protein samples (typically mixtures of
bradykinin fragment 1-5 and ACTH fragment 18-39 as
appropriate). Saturated -cyano-4-hydroxy-cinnamicacid (HCCA) matrix solution in 0.1% TFA/50% ACN
was mixed with the sample in 5:1 ratio and 1 l of the
mixture was spotted on a ground steel MTP384 target
(Bruker) and allowed to air dry. Samples were further
desalted by washing the dried spots with 1 l 0.1% TFA.
Nano-Liquid Chromatography Tandem Mass
Spectrometry (Nano-LC-MS/MS)
Nano-LC-MS/MS were performed on a hybrid quadru-
pole time-of-flight Q-TOF II (Micromass, Wythenshawe,
UK) mass spectrometer equipped with an orthogonal
nanospray source from New Objective, Inc. (Woburn,
MA) operated in positive ion mode. The LC system was a
Waters Capillary LC (Waters, Milford, MA). The mobile
phase A was water containing 50 mM acetic acid and the
mobile phase B was acetonitrile. Samples dried in the
speed vacuum were dissolved in 15 l acetic acid (50
mM). 2.5 l of the samples were injected onto the trapping
column (LC Packings, Sunnyvale, CA) and washed with
50 mM acetic acid. The injector port was switched to
inject and the peptides were eluted off the trap onto the
column. A 5 cm 75 m i.d. ProteoPep C18 column (New
Objective) packed directly in the nanospray tip was
used for chromatographic separations. Peptides were
eluted directly off the column into the Q-TOF system
using a gradient of 2 to 80% B over 30 min, with a flow
rate of 500 nl/min (precolumn split from 40 l/min).
The total run time was 55 min. The nanospray capillary
voltage was set at 3.0 kV and the cone voltage at 55 V.
The source temperature was maintained at 100 °C. Mass
spectra were recorded using MassLynx 4.0 with auto-
matic switching functions and were acquired frommass
400 to 2000 Da every second with a resolution of 8000
(FWHM). When a desired peak was detected at a
minimum of 15 ion counts, the mass spectrometer
automatically acquired CID MS/MS spectrum of the
individual peptide. Collision energy was set dependent
on charge state recognition properties. Sequence infor-
mation from the MS/MS data were processed using
Mascot Distiller. Database searches were performed
using Mascot MS/MS ion search (Matrix Science,
Boston MA) [40].
Micro-Liquid Chromatography Tandem
Mass Spectrometry (Micro-LC-MS/MS)
In-gel trypsin digests were also run on micro-LC cou-
pled with a Thermo Finnigan LCQ DECA XP ion trap
(San Jose, CA). MS/MS data were obtained from m/z
200 to 2000 to compensate for low m/z ions that may
have been missed in the nano-LC-MS/MS experiments.
Ten l of the in-gel digests were injected into a supelco
(Bellefonte, PA) biowide pore C18 column (15 cm 
1 mm, 5 m) connected to a Shimadzu capillary LC
(Columbia, MD). The mobile phase A was water with
0.1% formic acid and mobile phase B was acetonitrile
with 0.1% formic acid. Peptides were separated using a
1644 REN ET AL. J Am Soc Mass Spectrom 2005, 16, 1641–1653gradient of 5 to 75% B over 60 min. The total run time
was 80 min. Peptides eluted off the column flowed into
the ESI interface of the mass spectrometer. The capillary
voltage was maintained at 4.5 KV and the sheath gas
Figure 1. AU-PAGE separation of control, TSA, and DDP treated
histones.
Table 1. MALDI-TOF Data for TSA treated histone H4 acetylati
Isoform/coverage Measured (MH) Rel. abund. Cal
0 Ac 515.30 1.00
543.36 0.60
989.54 0.12
1180.56 0.040
1325.68 0.11
1 Ac 515.34 1.0
530.32 0.50
543.41 0.73
989.62 0.17
1180.65 0.09
1325.79 0.20
2 Ac 515.44 1.0
530.43 0.24
543.50 0.53
927.72 0.68
989.77 0.38
1180.83 0.34
1325.96 0.34
3 Ac 515.50 1.00
543.54 0.35
927.69 0.75
989.70 0.20
1180.70 0.11
1211.79 0.037
1325.82 0.33
1396.85 0.87
4 Ac 515.39 1.0
543.46 0.30
989.73 0.11
1180.76 0.046
1325.96 0.12
1439.04 0.54Note: The bolded peaks are confirmed by nano-LCMS/MS run on quadrupo
The others were verified by micro-LC-MS/MS run on LCQ DECA XP ion traflow was set to 40. A full mass scan was obtained from
200 to 2000 Da and data-dependent MS/MS spectra
were obtained for the three most intense precursor ions.
Database searches on the product ions were performed
the same as for the nano-LC-MS/MS data.
Results and Discussion
AU-PAGE Separation and Peptide Mass Mapping
Histone variants were separated by AU-PAGE based on
their acetylation state. The acetylated isoforms of his-
tones H4 and H3 were well separated by AU-PAGE
unlike the acetylated isoforms of histones H2A and
H2B, which overlapped with other bands (Figure 1).
Acetylation of H4 increased upon treatment with both
TSA and DDP. The NH2-terminal serine is assumed to
be acetylated in all isoforms. Three gel bands were
clearly observed for the untreated control correspond-
ing to the non-, mono-, and diacetylated isoforms (note:
to avoid confusion, this discussion keeps with the
tradition of labeling the first gel band as 0-Ac. Further-
more, this band is referred to as nonacetylated since it
has no acetylated lysines). The number of visible bands
oforms
ed (MH) Possible sequence Error (ppm)
5.34 36RLAR39 77.62
3.40 20KMe2VLR
23 73.61
9.58 60VFLENVIR67 40.42
0.62 46ISGLIYEETR55 50.82
5.75 24DNIQGITKPAIR35 52.80
5.34 36RLAR39 0.00
0.30 13GGAKAcR
17 37.71
3.40 20KMe2VLR
23 18.40
9.58 60VFLENVIR67 40.42
0.62 46ISGLIYEETR55 25.41
5.75 24DNIQGITKPAIR35 30.17
5.34 36RLAR39 194.05
0.30 13GGAKAcR
17 245.14
3.40 20KMe2VLR
23 184.03
7.54 9GLGKAcGGAKAcR
17 194.06
9.58 60VFLENVIR67 192.00
0.62 46ISGLIYEETR55 177.87
5.75 24DNIQGITKPAIR35 158.40
5.34 36RLAR39 306.98
3.40 20KMe2VLR
23 260.95
7.54 9GLGKAcGGAKAcR
17 164.31
9.58 60VFLENVIR67 122.88
0.62 46ISGLIYEETR55 66.58
1.69 6GGKAcGLGKAcGGAKAcR
17 85.83
5.75 24DNIQGITKPAIR35 49.71
6.80 4GKAcGGKGLGKAcGGAKAcR
17 34.01
4GKGGKAcGLGKAcGGAKAcR
17
5.34 36RLAR39 97.02
3.40 20KMe2VLR
23 110.42
9.58 60VFLENVIR67 151.58
0.62 46ISGLIYEETR55 118.58
5.75 24DNIQGITKPAIR35 158.40
8.81 4GKAcGGKAcGLGKAcGGAKAcR
17 159.85on is
culat
51
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Me2: Dimethylation; Me: Monomethylation; Ac: Acetylation; Rel. Aund.: Relative Abundance.
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(non-, mono-, di-, tri-, and tetraacetylated isoform of
histone H4). The gel bands were excised separately and
in-gel digested with trypsin to determine the posttrans-
lational modifications for each of the isoforms. The
masses for the peptides were determined from the
MALDI-TOF MS and were compared with theoretical
masses obtained by use of MS-Digest on the Protein
Prospector website (prospector.ucsf.edu) [41]. Modifi-
cations that were allowed in the theoretical digest
included: S/T/Y phosphorylation; NH2-terminus acet-
ylation; lysine mono-, di-, and trimethylation, lysine
acetylation, and oxidation of methionine (methylation
at arginine was not considered at this time). On aver-
age, the dynamic range between the highest and lowest
abundance peptides was 140.
Acetylation Patterns for TSA Treated Cells
To identify the modifications of H4 in the control cells
and in cells treated with HDAC inhibitors, a systematic
strategy was developed for the analysis of H4 isoforms
separated by AU-PAGE using mass spectrometry after
in-gel trypsin digestion. Arg-C digestion was also per-
formed but the results exhibited poorer reproducibility
than trypsin due to nonspecific cleavage at lysine resi-
dues (data not shown). In-gel digestion procedures for
Arg-C are still being developed as selective cleavage at
arginine is highly desirable. The peptides shown in
Figure 2. MALDI-TOF MS spectra of trypsin in
by AU-PAGE from TSA treated histones. Signal
are italicized. Trypsin autolysis products (842.
attributable to the coomassie stain (825.1 Th) aTable 1 were observed in the MALDI-TOF MS data fromthe TSA treated histones and confirmed by LC-MS/MS. A
full list of the MALDI-TOF MS masses is provided in the
Supplementary Material with the online version of this
article, along with their potential assignments as gener-
ated by protein prospector [41]. However, only the
assignments confirmed byMS/MS are discussed in the
following sections. The MALDI-TOF MS peptide map-
ping data in Figures 2 and 3 are discussed separately
from the supporting MS/MS data in Figures 4, 5, 6, 7, 8,
and 9.
Several peptides were observed in all gel bands in
MALDI-TOF MS. These included: the dimethylation of
K20 in fragment 20-23 (543.40 Th) and the unmodified
fragments 36-39 (515.30 Th), 60-67 (989.58 Th), 46-55
(1180.62 Th), 24-35 (1325.75 Th). In the first gel band
(Figure 2a), no lysine acetylation was observed. This is not
unexpected since the NH2-terminal serine is believed to be
predominantly acetylated. The only modification ob-
served was dimethylation of K20 as was shown by the
strong peak at 543.36 Th. However, fewer peaks were
observed compared with the other isoforms. This is be-
cause the tails of histone H4 are arginine- and lysine rich,
resulting in small fragments (500 Th) that were likely
obscured by strong signals from the matrix.
In the second gel band, K16 was found to be acetylated
as indicated by the presence of the peptide at 530.32 Th
corresponding to one acetylation in fragment 13-17, in
addition to the previously discussed dimethylation of K20
(Figure 2b). For the third gel band, a peptide at 927.72  Th
digests of different acetylation isoforms isolated
ibutable to the acetylation of the NH2-terminus
h) are indicated by two asterisks and signals
dicated by one asterisk.-gel
s attr
7 Twas observed (Figure 2c). This peptide corresponded to
 Th
1646 REN ET AL. J Am Soc Mass Spectrom 2005, 16, 1641–1653the addition of two acetyl groups to K12 and K16 in
fragment 9-17. The peak at 530.43 Th (K16 acetylation in
fragment 13-17) was still present although in lower abun-
Figure 3. MALDI-TOF MS spectra of trypsin
isolated by AU-PAGE from DDP treated hist
NH2-terminus are italicized. Trypsin autolysis pr
signals attributable to the coomassie stain (825.1
Figure 4. Nano-LC-MS/MS spectrum of the pr
from TSA treated diacetylation band. The same
observed in both the TSA and DDP treated triacetyladance as compared with the previous gel band. Since
trypsin is inhibited by lysine acetylation, the presence of
fragment 13-17 indicated acetylation somewhere else on
l digests (1 h) of different acetylation isoforms
Signals attributable to the acetylation of the
ts (842.7 Th) are indicated by two asterisks and
) are indicated by one asterisk.
or ion at 464.382 Th. These data were obtained
entation pattern of this precursor ion was alsoin-ge
ones.
oducecurs
fragmtion band.
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this band contains a mixture of isoforms in which (1) K12
is acetylated after K16 and (2) K16 is acetylated along with
another undetermined site on the molecule.
Figure 6. Nano-LC-MS/MS spectrum of precu
in fragment 4-17 was observed. The presenc
NH -terminus and y = indicated an additional p
Figure 5. Nano-LC-MS/MS spectrum of the pr
treated triacetylation band).2 12
from DDP treated triacetylation band).As was shown in Figure 2d for the fourth gel band,
two peptides were observed that correlated with the
acetylation of three lysine residues. The first of these
was a peptide (1211.79 Th) that corresponded to
on at 698.942 Th. K8, K12, and K16 acetylation
mass shift of 42 Da in the b ions near the
n of K5, K12, and K16 acetylation (data obtained
sor ion at 606.532 Th (data obtained from TSArsor i
e of
atterecur
1648 REN ET AL. J Am Soc Mass Spectrom 2005, 16, 1641–1653acetylated K8, K12, and K16 in fragment 6-17. The
second peptide (1396.85 Th) also corresponded to
three acetylated lysines in fragment 4-17. This fragment
contains 4 lysine residues, K5, K8, K12, and K16. It was
assumed that K12 and K16 remained acetylated leaving
either K5 or K8 as the next likely location for modifica-
tion. Nano-LC-MS/MS of the peptides in this digested
gel band showed the presence of two peptide sequences
in which K16, K12, and either K8 or K5 were acetylated
based on the observance of two y12 ions (1211.96
 and
1169.93, respectively). The y ions corresponded to
acetylation of K16, K12, and K8 were present at higher
abundance. The result is partially corroborated by the
presence of the diacetylated fragment 9-17. It was
inferred that K8 must be at least partially unmodified to
allow trypsin cleavage after K8, leading to the conclu-
sion that an additional acetylation was located on K5.
The abundance for the peptide at 1211.79 Th was very
low in the one h trypsin digestion (data not shown). Its
abundance increased as the digestion time increased to
two h, whereas that of the peptide at 1396.85 Th
decreased. This observation supports the presence of a
missed cleavage at K5, which would result in a lower
abundance of the peptide at 1211.79 Th. However,
little additional benefit was noted between the diges-
tion time of one h and two h.
The MALDI-TOF MS of the fifth gel band showed an
abundant peptide (1439.04 Th) that corresponded to
the fully acetylated fragment 4-17 (Figure 2e). No other
acetylated peptides described above were observed
indicating complete acetylation of the NH2-terminal
lysine residues of histone H4.
Figure 7. Nano-LC-MS/MS spectrum of prec
treated tetraacetylation band).Acetylation Patterns of DDP Treated Cells
The histone H4 modifications of DDP treated lym-
phosarcoma cells are summarized in Table 2. As
indicated above, only the assignments confirmed by
MS/MS are discussed in the following. The pattern of
peptides observed for the DDP treated cells is virtu-
ally identical to that observed for the TSA treated
cells (Figure 3). Some low abundance peptides ob-
served in the TSA treated cells were not observed in
DDP treated cells likely because of lower protein
concentration and experimental variance. However,
the pattern of modification follows the same trend
observed for TSA. K16 is initially acetylated, followed
by K12. The triacetylation isoform contains the addi-
tional acetylation of K5 or K8. Thus, the experiments
revealed no major differences in the NH2-terminal
specificity between TSA and DDP with the exception
that DDP is effective at much lower concentrations
(10 nM DDP compared with 300 nM TSA). No differ-
ences in the peptide identity and locations of modi-
fications were observed when compared with the
peptides from the gel bands of the untreated control
except that only three isoforms were observed in the
control (Table 3). For comparison, the MALDI-TOF
MS data are provided in the Supplementary Material
available online (Tables A1, A2, A3, Figures 1, 2, 3).
Verification of Acetylation Patterns by LC-MS/MS
Since MALDI-TOF MS does not have the mass accu-
racy to differentiate trimethylation and acetylation
ion at 719.952 Th (data obtained from DDPursor
from
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were also performed to verify the sequences and
modification patterns for each of the in-gel digests. In
addition to direct sequence information, MS/MS gen-
erates diagnostic fragments that aid in the assign-
ment. For example, trimethylated peptides yield y-59
Figure 8. Micro-LC-MS/MS spectrum of pre
acetylated in fragment 13 to 17 (data obtained
Figure 9. Micro-LC-MS/MS spectrum of pre
dimethylated in fragment 20 to 23 (data obtained froions and/or b-59 ions [29]. If the peptide is acety-
lated, y and b ions will be observed in addition to an
immonium ion 126  Th [29].
The precursor ion at 464.382 Th was assigned unam-
biguously by nano-LC-MS/MS to be acetylation at K12
and K16 in fragment 9-17. The immonium ion at 126.14
r ion at 265.912 Th. K16 was verified to be
DDP treated diacetylation band).
r ion at 272.642 Th. K20 was verified to becursocurso
m DDP treated diacetylation band).
rupo
on tra
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TOF MS peak at 927.76 Th as 9GLGKAcGGAKAcR
17
(Figure 4). Using the same strategy, the monoisotopic
peak at 1211.79 Th fromMALDI-TOF MS was identified
as 6GGKAcGLGKAcGGAKAcR
17 from the nano-LC-MS/MS
data of precursor ion 606.53 2  Th (Figure 5). This assign -
ment confirms the absence of the isobaric unmodified
fragment 92-102 that could also occur at 1211.63 Th. The
monoisotopic peak at 1396.85 Th has three lysines acety-
lated among four lysines in fragment 4-17 giving rise to
four possible isoforms. Nano-LC-MS/MS showed that
K12 and K16 were acetylated. However, closer inspection
of the data revealed two sets of NH2-terminal b and y ions
differing in mass by 42 Da. Although the product ion for
K5 acetylation b2=(228.20), b3=(285.23), b4= (342.27)
might also be assigned as internal fragment ions, the
unique y12= (1169.93) supports K5 as another site of
acetylation. Thus, this peak is from a mixture of peptides
where either K5 or K8 were acetylated. The sequences for
these monoisotopic peaks were 4GKGGKAcGLGKAcG-
GAKAcR
17 and 4GKAcGGKGLGKAcGGAKAcR
17 (Figure 6).
The peptide with monoisotopic mass 1439.04 Th was
Table 2. MALDI-TOF Data for depsipeptide treated histone H4
Isoform/coverage Measured (MH) Rel. abund. Cal
0 Ac 515.40 1.00
543.47 0.65
989.74 0.13
1180.79 0.033
1325.98 0.088
1 Ac 515.36 0.35
530.33 0.18
543.42 0.27
989.65 0.18
1180.74 0.004
1325.82 0.010
2 Ac 515.40 0.46
530.39 0.078
543.47 0.29
927.65 0.16
989.67 0.031
1180.71 0.015
1325.87 0.039
3 Ac 515.45 1.00
543.52 0.38
927.73 0.58
989.80 0.23
1180.87 0.14
1211.92 0.037
1326.01 0.18
1397.06 0.048
4 Ac 515.44 0.37
543.51 0.30
989.74 0.040
1180.86 0.017
1325.99 0.027
1439.06 0.54
Me2: Dimethylation; Me: Monomethylation; Ac: Acetylation; Rel. Abun
Note: The bolded peaks are confirmed by nano-LCMS/MS run on quad
The others were verified by micro-LC-MS/MS run on LCQ DECA XP iestablished by nano-LC-MS/MS to be the acetylation ofK5, K8, K12, and K16 in fragment 4-17 from the precursor
ion at 719.952 Th (Figure 7) excluding assignment to the
unmodified isobaric fragment 79-91 (1438.80 Th).
For the low mass precursor ions, micro-LC-MS/MS
data were obtained to verify their sequence. For the
peptide at 515.30 Th, there are three possible se-
quences based on the monoisotopic mass: 37LARR40,
36RLAR39, or 20KVLR23. MS/MS of the precursor ion at
258.372 Th revealed its sequence as 36RLAR39 (see
supplementary data). Using the same method, the pre-
cursor ion at 265.912 corresponded to acetylation of
K16 in fragment 13-17 (Figure 8) and the precursor ion
at 272.642 confirmed the dimetylation of K20 in
20KMe2VLR
23 (Figure 9). A singly charged precursor ion
at 543.30 was also fragmented and further verified the
dimethylation of K20 in fragment 20-23 (see Supple-
mentary Material).
Acetylation Patterns of Histone H4
Histone acetylation has been widely studied due to
its significant role in nucleosome assembly. More
lation isoforms
ed (MH) Sequence Error (ppm)
5.34 36RLAR39 112.93
3.40 20KMe2VLR
23 132.13
9.58 60VFLENVIR67 163.30
0.62 46ISGLIYEETR55 142.81
5.75 24DNIQGITKPAIR35 170.39
5.34 36RLAR39 38.81
0.30 13GGAKAcR
17 56.57
3.40 20KMe2VLR
23 40.12
9.58 60VFLENVIR67 70.74
0.62 46ISGLIYEETR55 101.64
5.75 24DNIQGITKPAIR35 52.80
5.34 36RLAR39 112.93
0.30 13GGAKAcR
17 169.72
3.40 20KMe2VLR
23 132.13
7.54 9GLGKAcGGAKAcR
17 121.18
9.58 60VFLENVIR67 92.56
0.62 46ISGLIYEETR55 92.56
5.75 24DNIQGITKPAIR35 87.42
5.34 36RLAR39 161.24
3.40 20KMe2VLR
23 224.15
7.54 9GLGKAcGGAKAcR
17 207.43
9.58 60VFLENVIR67 223.93
0.62 46ISGLIYEETR55 210.57
1.69 6GGKAcGLGKAcGGAKAcR
17 189.82
5.75 24DNIQGITKPAIR35 193.02
6.80 4GKAcGGKGLGKAcGGAKAcR
17 184.35
4GKGGKAcGLGKAcGGAKAcR
17
5.34 36RLAR39 190.55
3.40 20KMe2VLR
23 205.74
9.58 60VFLENVIR67 163.30
0.62 46ISGLIYEETR55 202.10
5.75 24DNIQGITKPAIR35 177.94
8.81 4GKAcGGKAcGLGKAcGGAKAcR
17 182.10
lative Abundance.
le Time-of-flight Q-Tof II.
p.acety
culat
51
54
98
118
132
51
53
54
98
118
132
51
53
54
92
98
118
132
51
54
92
98
118
121
132
139
51
54
98
118
132
143
d.: Reimportantly acetylation does not appear to be ran-
rupo
on tra
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be diacetylated exclusively on K5 and K12 by histone
acetyltransferase B (HAT B) [42, 43]. This was con-
firmed by the acetylation patterns of Drosophila [42]
and Tetrahemena [44]. Couppez showed that K12 was
acetylated first, then K5 and K16 in cuttlefish testis
[45]. They also showed that K16 was primarily acety-
lated followed by K12, K5 or K8 in calf thymus [45].
K16 was predominately acetylated in histone H4 of
both pig thymus and HeLa cells, but the progressive
addition of acetyl groups to K12, K8 and K5 was less
specific [46]. Turner studied histone H4 acetylation in
human cells by immunolabeling with site-specific
antibodies and found out that K16 was the preferred
site of acetylation, followed by K12, K8 and K5 [47].
Zhang proposed a “zip” model for histone acetyla-
tion and deacetylation based on their study of histone
H4 in HeLa S3 cells treated with sodium butyrate by
use of mass spectrometry [24]. They suggested that
histone H4 in HeLa S3 cells was primarily acetylated
at K16, followed by K12, K8 and K5 in that strict
order. Histone deacetylation occurred in the reverse
direction: K5 first, then K8, K12 and K16. K20 was
predominantly dimethylated in all isoforms, which
may have some effect on histone acetylation and
deacetylation. In their work they examined the crude
mixture of histone H4 in which all isoforms were
present. It was thus hard to distinguish which mod-
ifications were associated with a particular acetyla-
tion isoform.
In our study, the acetylation isoforms of histone
H4 were separated by AU-PAGE and the resolved
isoforms were in-gel digested and mass analyzed.
Our data showed that K16 is acetylated first in mouse
lymphosarcoma cells followed by K12. However, we
Table 3. MALDI-TOF Data for control histone H4 acetylation is
Isoform/coverage Measured (MH) Rel. abund.
0 Ac 515.43 1.00
543.50 0.73
989.79 0.32
1180.87 0.17
1326.03 0.12
1 Ac 515.46 0.74
530.45 0.48
543.53 0.52
989.86 0.23
1180.95 0.17
1326.11 0.43
2 Ac 515.43 0.78
530.42 0.14
543.48 0.14
927.75 0.13
989.81 0.035
1180.88 0.020
1326.06 0.044
Me2: Dimethylation; Me: Monomethylation; Ac: Acetylation; Rel. Abun
Note: The bolded peaks are confirmed by nano-LCMS/MS run on quad
The others were verified by micro-LC-MS/MS run on LCQ DECA XP iobserved that both K8 and/or K5 may be acetylatednext. In the triacetylated gel bands we observed a
mixture of K5 and K8 acetylation that was confirmed
by tandem mass spectrometry. More importantly, the
pattern of acetylation upon treatment with TSA and
DDP was conserved and indicates that these drugs
may induce similar, if not the same, physiological
response. In all of the acetylated isoforms of histone
H4 with or without treatment of HDAC inhibitor, K20
was always predominantly dimethylated. K20
monomethylation in fragment 20-23 was also ob-
served as was indicated by the peptide at 529.4 Th
(see supplementary data). However no MS/MS data
were obtained due to its low abundance. The mo-
noisotopic mass of the same peptide with unmodified
K20 overlapped with that of fragment of 36-39 and
fragment 27-40. Micro-LC-MS/MS data confirmed
that peptide to be unmodified fragment of 36-39.
Lindner et al. reported an increased trimethylation of
K20 in histone H4 in hypoacetylated isoforms [48]. In
our study, trimethylation of K20 was not observed or
buried under background.
Finally, interplay among different acetylation,
methylation, and phosphorylation sites of histone is
important. For example, such interplay between site
on H3 has been reported in Xenopus oocytes [49].
Western blot analysis revealed an increase in meth-
ylation of K4, increase in dual modification of S10-P/
K14-Ac, and decrease in methylation of H3-K9 fol-
lowing treatment with TSA. It will be of interest to
investigate whether there is cross talk among differ-
ent posttranslational modifications of H3 induced by
HDAC inhibitors in mammalian cells. We want to
pursue this by employing mass spectrometry instead
of western blot analysis, which may not provide an
s
alculated (MH) Sequence Error (ppm)
515.34 36RLAR39 171.15
543.40 20KMe2VLR
23 187.34
989.58 60VFLENVIR67 213.83
1180.62 46ISGLIYEETR55 210.57
1325.75 24DNIQGITKPAIR35 208.11
515.34 36RLAR39 180.65
530.30 13GGAKAcR
17 273.24
543.40 20KMe2VLR
23 242.55
989.58 60VFLENVIR67 284.57
1180.62 46ISGLIYEETR55 265.03
1325.75 24DNIQGITKPAIR35 278.33
515.34 36RLAR39 171.15
530.30 13GGAKAcR
17 216.67
543.40 20KMe2VLR
23 150.53
927.54 9GLGKAcGGAKAcR
17 228.99
989.58 60VFLENVIR67 234.04
1180.62 46ISGLIYEETR55 219.04
1325.75 24DNIQGITKPAIR35 230.74
lative Abundance.
le Time-of-flight Q-Tof II.
p.oform
C
d.: Reaccurate picture if the antibody is not highly specific.
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The present study was undertaken to explore the acet-
ylation patterns of histone H4 after treatment with
HDAC inhibitors. To address this question, different
acetylation isoforms of histone H4 were separated first
by AU-PAGE; then MALDI-TOF MS and nano- or
micro-LC-MS/MS was performed to give a systematic
analysis. Our study demonstrates the successful appli-
cation of peptide mass fingerprinting on tryptic in-gel
digests after the separation of acetylation isoforms by
AU-PAGE. MALDI-TOF MS data identified the trend of
acetylation for the HDAC inhibitor TSA and DDP
treated histones on the NH2-terminal residues. In his-
tone H4 of mouse lymphosarcoma cells, K16 is prefer-
entially acetylated, followed by K12, K8, and/or K5.
Nano- or micro-LC-MS/MS of the in-gel digests veri-
fied the modification patterns.
HDAC inhibitors also play an important role in the
reversible acetylation of nonhistone DNA binding pro-
teins such as p53 [50] and NF-kB [51]. Likely, many key
cellular proteins are hyperacetylated in cells treated
with TSA or DDP. It will be important to identify these
proteins specifically in cancer cells that are sensitive or
resistant to HDAC inhibitors by employing whole cell
proteomics. Studies along these lines are our goals in
the future.
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